The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ACADIA PHARMACEUTICALS INC | COM | 004225108 | 20,284,524 | 846,953 | SH | SOLE | 846,953 | 0 | 0 | |||
AFTERNEXT HEALTHTECH ACQUISITION CORP | *W EXP 99/99/999 | G01109126 | 31,753 | 366,666 | SH | SOLE | 366,666 | 0 | 0 | |||
AMICUS THERAPEUTICS INC | COM | 03152W109 | 16,651,734 | 1,325,775 | SH | SOLE | 1,325,775 | 0 | 0 | |||
APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 22,017,959 | 241,690 | SH | SOLE | 241,690 | 0 | 0 | |||
ARES ACQUISITION CORP | *W EXP 02/02/202 | G33032122 | 403,765 | 504,706 | SH | SOLE | 504,706 | 0 | 0 | |||
ARVINAS INC | COM | 04335A105 | 10,213,430 | 411,500 | SH | SOLE | 411,500 | 0 | 0 | |||
ASCENDIS PHARMA A/S | SPONSORED ADR | 04351P101 | 12,474,651 | 139,772 | SH | SOLE | 139,772 | 0 | 0 | |||
BAUSCH HEALTH COS INC | COM | 071734107 | 9,320,000 | 1,165,000 | SH | SOLE | 1,165,000 | 0 | 0 | |||
BILANDER ACQUISITION CORP | *W EXP 05/19/202 | 09001T114 | 9,334 | 183,749 | SH | SOLE | 183,749 | 0 | 0 | |||
BRIDGETOWN HOLDINGS LTD | *W EXP 09/30/202 | G1355U121 | 221,960 | 895,000 | SH | SOLE | 895,000 | 0 | 0 | |||
CEREVEL THERAPEUTICS HLDNG I | COM | 15678U128 | 15,658,006 | 492,545 | SH | SOLE | 492,545 | 0 | 0 | |||
CHURCHILL CAPITAL CORP V | *W EXP 10/29/202 | 17144T115 | 110,221 | 612,000 | SH | SOLE | 612,000 | 0 | 0 | |||
CHURCHILL CAPITAL CORP VI | *W EXP 02/17/202 | 17143W119 | 97,200 | 540,000 | SH | SOLE | 540,000 | 0 | 0 | |||
CHURCHILL CAPITAL CORP VII | *W EXP 02/29/202 | 17144M110 | 76,720 | 548,000 | SH | SOLE | 548,000 | 0 | 0 | |||
CLARIVATE PLC | ORD SHS | G21810109 | 11,887,779 | 1,247,406 | SH | SOLE | 1,247,406 | 0 | 0 | |||
COMPASS DIGITAL ACQUISITION CORP | *W EXP 09/29/202 | G2476C123 | 68,434 | 459,906 | SH | SOLE | 459,906 | 0 | 0 | |||
CONCORD ACQUISITION CORP II | *W EXP 99/99/999 | 20607U116 | 16,333 | 408,333 | SH | SOLE | 408,333 | 0 | 0 | |||
CONYERS PARK III ACQUISITION CORP | *W EXP 08/12/202 | 21289P110 | 28,583 | 571,666 | SH | SOLE | 571,666 | 0 | 0 | |||
CORSAIR PARTNERING CORP | *W EXP 07/06/202 | G2540H116 | 0 | 334,666 | SH | SOLE | 334,666 | 0 | 0 | |||
CRINETICS PHARMACEUTICALS IN | COM | 22663K107 | 14,371,437 | 797,527 | SH | SOLE | 797,527 | 0 | 0 | |||
CYTOKINETICS INC | COM NEW | 23282W605 | 12,039,814 | 369,093 | SH | SOLE | 369,093 | 0 | 0 | |||
FIRST LIGHT ACQUISITION GROUP INC | *W EXP 03/14/202 | 320703119 | 85,176 | 655,200 | SH | SOLE | 655,200 | 0 | 0 | |||
GALAPAGOS NV | SPON ADR | 36315X101 | 16,542,887 | 406,859 | SH | SOLE | 406,859 | 0 | 0 | |||
HOME PLATE ACQUISITION CORP | *W EXP 09/30/202 | 43734R111 | 14,697 | 690,000 | SH | SOLE | 690,000 | 0 | 0 | |||
MARBLEGATE ACQUISITION CORP | *W EXP 08/31/202 | 56608A113 | 41,307 | 735,000 | SH | SOLE | 735,000 | 0 | 0 | |||
MOONLAKE IMMUNOTHERAPEUTICS | CLASS A ORD | 61559X104 | 15,402,000 | 302,000 | SH | SOLE | 302,000 | 0 | 0 | |||
MORPHIC HOLDING INC | COM | 61775R105 | 16,485,585 | 287,556 | SH | SOLE | 287,556 | 0 | 0 | |||
PROTHENA CORP PLC | SHS | G72800108 | 21,665,244 | 317,300 | SH | SOLE | 317,300 | 0 | 0 | |||
RELAY THERAPEUTICS INC | COM | 75943R102 | 8,811,719 | 701,570 | SH | SOLE | 701,570 | 0 | 0 | |||
ROSS ACQUISITION CORP II | *W EXP 02/01/202 | G7641C114 | 74,435 | 439,666 | SH | SOLE | 439,666 | 0 | 0 | |||
SAGE THERAPEUTICS INC | COM | 78667J108 | 16,822,110 | 357,765 | SH | SOLE | 357,765 | 0 | 0 | |||
SAREPTA THERAPEUTICS INC | COM | 803607100 | 14,367,336 | 125,457 | SH | SOLE | 125,457 | 0 | 0 | |||
SOLID BIOSCIENCES INC | COM NEW | 83422E204 | 5,036,955 | 961,251 | SH | SOLE | 961,251 | 0 | 0 | |||
SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 15,958,226 | 608,628 | SH | SOLE | 608,628 | 0 | 0 | |||
SWIFTMERGE ACQUISITION CORP | *W EXP 12/13/202 | G63836111 | 48,020 | 490,000 | SH | SOLE | 490,000 | 0 | 0 | |||
TRAVERE THERAPEUTICS INC | COM | 89422G107 | 11,700,035 | 761,721 | SH | SOLE | 761,721 | 0 | 0 | |||
YS BIOPHARMA CO LTD | *W EXP 03/15/202 | G9845F117 | 23,030 | 489,999 | SH | SOLE | 489,999 | 0 | 0 |